Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialYukio Kondo, Fredrik Schjesvold, Albert Oriol et al.|The Lancet Haematology|2019Cited by 247
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European PerspectiveHeinz Ludwig, Antonio Palumbo, Joan Bladé et al.|The Oncologist|2011Cited by 33
Myeloma in Scar Tissue - An Underreported Phenomenon or an Emerging Entity in the Novel Agents' Era? A Single Center SeriesEli Muchtar, Hila Magen‐Nativ, Pia Raanani et al.|Acta Haematologica|2014Cited by 19